CAR-T pioneer receives American Society of Gene and Cell Therapy’s highest honor
Click Here to Manage Email Alerts
Michel Sadelain, MD, PhD, will receive this year’s Outstanding Achievement Award from the American Society of Gene and Cell Therapy for his research on chimeric antigen receptors.
The award — American Society of Gene and Cell Therapy’s (ASGCT) highest honor — recognizes a society member for “a pioneering research success, specific high-impact accomplishment or lifetime of significant contributions to the field of gene and cell therapy,” according to a society-issued press release.
Sadelain is director of Center for Cell Engineering at Memorial Sloan Kettering Cancer Center. He also is a member of the Cell Therapy Next Peer Perspective Board.
Sadelain will deliver the George Stamatoyannopoulos Memorial Lecture during this year’s virtual ASGCT Annual Meeting, which will be held May 11-14.
Sadelain’s plenary lecture on May 12 will highlight his previous and ongoing research on CAR T-cell therapy.
“I am delighted and honored to have been selected as a recipient of this very prestigious award from the ASGCT,” Sadelain said in the release. “The ASGCT has a long-standing commitment to support the basic science and clinical translation of gene and cell therapies, from genetic disorders to mRNA-based vaccines. This award celebrates the transformative nature of T cell engineering and CAR therapy.”
Click Here to Manage Email Alerts